Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck reveals 2005 financials

Lundbeck reveals 2005 financials

15th March 2006

Lundbeck has announced that its annual report for 2005 has been approved, with European revenue noting a marked improvement on 2004 figures.

The Danish-based pharmaceutical company has said that revenue from Europe rose by 11 per cent in 2005, or approximately ?470 million.

Total revenue for 2005 stood at approximately ?840 million across all markets, which was a decrease of approximately four per cent in local currency terms.

Lundbeck said that 69 per cent of the company’s total revenue was derived from the sale of new products, such as Cipralex and Ebixa. Cipralex was the company’s bestseller, experiencing 67 per cent sales growth in the fourth quarter of 2005.

The company is expecting the total amount spent on investments to rise slightly in 2006, but has implied that all other areas will fall, including a profit from operations expected fall of approximately ?55 million.

Lundbeck, which researches, develops, manufacturers and markets drugs for the treatment of psychiatric and neurological disorders, has said that the full print version of the report will be published in early April.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.